



ADVANCING SCIENCE

in the Fast Growing Pharmaceutical and Biotechnology Sector

Q2 2022 Earnings Call | August 4, 2022

DISCLAIMER

Certain statements made in this Q2 2022 earnings call presentation, including responses to questions, may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.

For additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, please consult the MD&A for this quarter, the Risk Factors section of the Annual Information Form and DRI Healthcare Trust's other filings with Canadian securities regulators. DRI Healthcare Trust does not undertake to update any forward-looking statements; such statements speak only as of the date made.

This earnings call presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts, Total Cash Royalty Receipts, and Adjusted EBITDA, and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under IFRS and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of DRI Healthcare Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS.

All dollar figures in this presentation are stated in US dollars.

ADVANCING OUR STRATEGY

Cash flow growth

- \$24.5 million transaction for pegcetacoplan royalty with option to increase exposure



Poised to execute

- \$283 million credit facility availability
- >\$1 billion in pipeline



Unitholder returns

- Declared distribution of \$0.075 per unit



Q2 FINANCIAL HIGHLIGHTS

| | |
|--|-----------------------|
| Total Income | \$21.3 million |
| Net Earnings and Other Comprehensive Earnings | \$3.1 million |
| Total Cash Receipts ⁽¹⁾ | \$25.3 million |
| Adjusted EBITDA ⁽¹⁾ | \$21.4 million |
| Adjusted Cash Earnings per Unit ⁽¹⁾ | \$0.43 |

PEGCETACOPLAN ROYALTY TRANSACTION



**Long-term horizon and
attractive growth prospects**



- Empaveli[®] (pegcetacoplan) (marketed as Aspaveli[®] in EU) represents a significant advancement in the standard of care for paroxysmal nocturnal hemoglobinuria
- \$24.5 million purchase price funded from cash on hand
- <1% royalty on worldwide net sales up to \$500 million per annum
- Option to increase the annual sales cap to \$1.1 billion in return for a one-time payment of \$21.0 million
- Extends portfolio duration to approx. 9 years
- Pegcetacoplan is also in development for pipeline indications including Geographic Atrophy (“GA”), Cold Agglutinin Disease and C3 glomerulopathy
- FDA has accepted NDA with priority review for GA indication with PDUFA target action date of November 26, 2022

ASSET PERFORMANCE

| | (\$ thousands) | Total Cash Royalty Receipts ⁽¹⁾ | | | | |
|-----------------|--|--|---------------|--------------|---------------|------------|
| | | Q2 2022 | Q2 2021 | % Change | Q1 2022 | % Change |
| Core Products | Eylea | 2,875 | 4,352 | (34%) | 2,946 | (2%) |
| | FluMist | - | 23 | (100%) | 2,218 | (100%) |
| | Natpara | 649 | 513 | 27% | 673 | (4%) |
| | Oracea | 1,959 | - | n/a | 1,749 | 12% |
| | Rydapt | 2,335 | 3,856 | (39%) | 2,963 | (21%) |
| | Spinraza | 4,573 | 5,615 | (19%) | 4,278 | 7% |
| | Vonjo | 220 | - | n/a | - | n/a |
| | Xolair | 1,458 | 1,417 | 3% | 2,641 | (45%) |
| | Zytiga ⁽²⁾ | 8,958 | 9,498 | (6%) | - | n/a |
| | Total Core Products | 23,027 | 25,274 | (9)% | 17,468 | 32% |
| Mature Products | Autoimmune Portfolio ⁽³⁾ | 576 | 1,747 | (67%) | 1,810 | (68)% |
| | Rilpivirine Portfolio ⁽⁴⁾ | - | 5,901 | (100%) | - | n/a |
| Other Products | Various | 419 | 407 | 3% | 424 | (1%) |
| | Total Cash Royalty Receipts⁽¹⁾ | 24,022 | 33,329 | (28%) | 19,702 | 22% |

STRONG CASH GENERATION

Adjusted EBITDA for the Six Months Ended June 30, 2022 (\$M)⁽¹⁾



WELL CAPITALIZED FOR GROWTH

- As at June 30, 2022:
 - \$43.0 million of cash and cash equivalents
 - Pegcetacoplan transaction closed using cash on hand
 - \$27.5 million of royalties receivable
 - \$67.0 million drawn on credit facilities
- Credit facility: Total size of \$350 million
 - \$283 million available credit as at June 30, 2022

OUR KEY PRIORITIES

Grow asset base

Execute on strong pipeline to acquire royalties on high quality assets that meet our investment criteria



Accretive growth

Focus on long-term, sustainable growth in top line royalty receipts and cash flow per unit



Unitholder returns

Continue focus on unitholder returns and appropriate distribution policy

